LEXG-Lexicon Genetics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics

LXRX 1.380

+3.0%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (110)	2/11/2002 9:21:32 AM
From: nigel bates	of 254

Deltagen and Merck Enter Into DeltaBase License Agreement REDWOOD CITY, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Deltagen, Inc. (Nasdaq: DGEN - news) announced today that it has entered into a license agreement to provide Merck & Co., Inc. (NYSE: MRK - news) with access to Deltagen's proprietary DeltaBase(TM) product, a powerful resource tool for the understanding of in vivo mammalian gene function information. Merck will have non-exclusive access to information related to 750 genes selected for their biological interest that have been functionally characterized and entered into DeltaBase. Merck will also have access to certain of the corresponding DeltaBase intellectual property rights. Financial terms were not disclosed. ``We are delighted to extend our relationship with Merck, which has a worldwide reputation in pharmaceutical discovery and development, by adding them as a DeltaBase subscriber,'' said William Matthews, Ph.D., president and chief executive officer at Deltagen...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next